Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ready To Change Bioequivalence Standards, Pending Advisory Committee Input

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency appears ready to narrow bioequivalence standards across the board for generic drug approvals and set up specific requirements for certain drugs with complicated dosing, but is looking to the Pharmaceutical Science advisory panel for final advice on whether the moves are necessary.

You may also be interested in...



ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies

FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.

ANDAs For Narrow Therapeutic Index Drugs May Need Crossover Studies

FDA’s challenges in creating a more specific definition of narrow therapeutic index drugs were on clear display at the most recent advisory committee meeting on the topic: There’s wide support for the project, but equally broad concern that it needs to be more carefully tailored.

Generics For Risperdal Consta Need Multi-Dose Testing, J&J Argues

Citizen petition tells FDA not to worry about bioequivalence tests in fasting patients, but focus on the product's three-stage release characteristics.

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel